Podium Session 5: Prostate Cancer
نویسندگان
چکیده
منابع مشابه
Session IV: Prostate Prostate cancer and imaging
Prostate cancer’s incidence, prevalence, etiology, and risk factors, and the influence of clinical trials on imaging technology development are discussed. One in seven Western men older than 70 will develop prostate cancer. The advent of prostate-specific antigen (PSA) screening means most men will now be diagnosed with early disease (85% not palpable on digital rectal exam (DRE), fewer grade 8...
متن کاملPodium for the opposition?
This is quite a paradoxical era. Scientific research is in its most productive phase and it continues to produce many beneficial technologies for mankind. For example, we rapidly progress towards a better understanding of many diseases and come up with multiple new approaches to cure them. At the same time, however, the voices against science and technology have never been more shrill. But unsu...
متن کاملPSA Screening in Prostate Cancer
Introduction: Prostate cancer is one of the most common cancers in Iranian men. PSA(prostate specific antigen) screening is a controversial issue because PSA screening leads to diagnose of patients with low risk prostate cancer who not only do not benefit from treatment but also suffer from complication caused by treatment. On the other hand, without prostate cancer screening, the rate of meta...
متن کاملSession 5 : Molecular Biology
not provided. [09.30–09.50] ‘Rapid discovery and optimization of therapeutic human antibodies using Adimabs yeast based discovery platform’ Jonathan Belk Adimab Inc., Lebanon, NH, USA We have created a synthetic antibody library with diversity that closely mimics the key features of the pre-immune process of VDJ recombination. This library has been synthesized and introduced into a novel yeast ...
متن کاملERK 5 Expression in Human Prostate Cancer
The MEK5/ERK5 pathway has recently been implicated in prostate and breast carcinogenesis. Over-expression of MEK5 is associated with aggressive prostate cancer. In this study, we examined the role of ERK5 (a MAPK and specific substrate for MEK5) in prostate cancer. ERK5 immunoreactivity is significantly upregulated in prostate cancer (PC) (n=81) when compared to BPH (n=20) (P<0.0001). Increased...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Canadian Urological Association Journal
سال: 2012
ISSN: 1920-1214,1911-6470
DOI: 10.5489/cuaj.1309